Cagrilintide Results Timeline: What Studies Measured, and When

Questions about "when results appear" with cagrilintide can only be answered indirectly, because clinical trials do not track individuals continuously. They measure pre-specified endpoints at pre-specified visits. Understanding the cagrilintide evidence base therefore means understanding the architecture of the trials: how long each ran, when dose escalation finished, and at which weeks researchers took measurements. This page maps that architecture using only published trial reports and reviews. It makes no claim about what any individual would experience.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no timeline below should be read as a prediction.

What Cagrilintide Is, in the Literature

Cagrilintide was described in the medicinal chemistry literature as a long-acting amylin analogue engineered for once-weekly administration, and the development paper set out the design work behind that molecule (PMID 34288673). A review of amylin analogues for obesity without diabetes placed cagrilintide within the broader amylin-receptor agonist class and discussed the present and future state of that class (PMID 39317404). A pharmacology handbook chapter on drugs for treating obesity likewise situated amylin analogues among obesity pharmacotherapies (PMID 34783910). The weekly dosing interval matters for timeline questions: it means trial protocols escalated doses over weeks, not days.

Trial Durations at a Glance

The table below lists the published cagrilintide studies and the total duration each ran, as reported in the trial publications themselves.

Weeks 0–20: The Phase 1b Window

The earliest published human timepoints for cagrilintide combined with semaglutide came from a randomised, controlled phase 1b trial that evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of cagrilintide given with semaglutide 2.4 mg over 20 weeks for weight management (PMID 33894838). Because it was a phase 1b design, the study was structured around pharmacokinetic and pharmacodynamic sampling and tolerability observation rather than around a single confirmatory efficacy endpoint; researchers reported on concomitant administration of multiple cagrilintide dose levels alongside a fixed semaglutide dose (PMID 33894838).

For anyone mapping a timeline, the important structural point is that 20 weeks was the outer limit of observation in that study. Any question about what happens after week 20 with that specific combination was not answerable from the phase 1b data alone (PMID 33894838).

Weeks 0–26: The Dose-Finding Phase 2 Trial

The multicentre, randomised, double-blind, placebo-controlled and active-controlled dose-finding phase 2 trial of once-weekly cagrilintide in people with overweight and obesity was the first large monotherapy dataset, and it tested a range of cagrilintide dose levels against both placebo and an active comparator (PMID 34798060). A dose-finding design means the trial's purpose was to compare dose levels against each other at a common endpoint rather than to establish a definitive effect size for one dose (PMID 34798060).

Why the escalation period matters to timeline questions

In dose-finding trials of once-weekly agents, participants do not receive the top dose on day one. A portion of the total trial duration is consumed by stepwise escalation, so measurements taken early in the study reflect sub-maximal exposure. The 26-week endpoint in the cagrilintide dose-finding trial therefore represented a period that included both escalation and maintenance, and the published report described the trial as dose-finding across that window (PMID 34798060). Reviews of amylin analogues in obesity have discussed this class-wide feature of dosing schedules (PMID 39317404).

Weeks 0–32: Type 2 Diabetes, Phase 2

A multicentre, randomised, double-blind, active-controlled phase 2 trial examined the efficacy and safety of once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg in people with type 2 diabetes (PMID 37364590). The active-controlled structure meant the comparison was against another active treatment rather than placebo, which changes how differences at the endpoint should be read (PMID 37364590).

The 32-week horizon in that trial sat between the 26-week dose-finding window and the 68-week phase 3 programme. That progression — 20, then 26, then 32, then 68 weeks — is the actual shape of the cagrilintide evidence timeline, and each step was a separate study with its own population, not a continuation of the last (PMID 34798060, PMID 37364590).

Weeks 0–68: The Phase 3 Timepoint

Two phase 3 reports published in 2025 established 68 weeks as the principal endpoint for the cagrilintide–semaglutide combination. One reported on coadministered cagrilintide and semaglutide in adults with overweight or obesity (PMID 40544433). The other reported on cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes (PMID 40544432). The separation of those two populations into distinct trials is itself informative: researchers did not assume that findings in one group would transfer to the other (PMID 40544433, PMID 40544432).

What 68 weeks does and does not tell you

A 68-week endpoint describes the state of the measured outcomes at week 68 in the enrolled population. It does not describe the trajectory of any individual, nor what occurs after treatment ends, nor what occurs beyond week 68 — those questions were outside the reported scope of both phase 3 publications (PMID 40544433, PMID 40544432).

How Cagrilintide Appears in Comparative Syntheses

Evidence syntheses aggregate across trials with different durations, which is a recognised limitation when reading timeline questions. A systematic review and network meta-analysis published in 2026 compared the effects of drugs for adults with overweight or obesity across the available randomised evidence (PMID 42419792). A separate 2024 systematic review and network meta-analysis examined GLP-1 receptor agonists for glycaemic control, body weight and lipid profile in type 2 diabetes (PMID 38286487). A 2025 clinical review of weight management treatment in obesity summarised the pharmacological landscape as it stood (PMID 40865172). When these syntheses pool trials that ran for 26, 32 or 68 weeks, a single pooled estimate no longer corresponds to a specific week (PMID 42419792).

Adverse Events Across the Trial Timeline: What Studies Report

Tolerability in the cagrilintide programme was assessed across the full duration of each trial rather than at a single visit. The phase 1b trial's stated remit included safety and tolerability of multiple cagrilintide doses given with semaglutide 2.4 mg over its 20-week course (PMID 33894838). The phase 2 dose-finding trial was placebo-controlled and active-controlled, which allowed adverse events on cagrilintide to be set against both a placebo arm and an active arm over 26 weeks (PMID 34798060). The phase 2 diabetes trial explicitly reported on efficacy and safety of cagrilintide 2.4 mg with semaglutide 2.4 mg (PMID 37364590).

At the phase 3 stage, safety reporting extended across the 68-week windows in both the overweight/obesity trial (PMID 40544433) and the trial in adults with overweight or obesity and type 2 diabetes (PMID 40544432). Class-level discussion of amylin analogue tolerability appears in the review literature on amylin analogues for obesity without diabetes (PMID 39317404) and in the obesity pharmacotherapy handbook chapter (PMID 34783910). Readers looking for specific event rates should consult the primary publications directly; this page does not reproduce them.

Where Timeline Data Is Absent

• Beyond 68 weeks. The longest published cagrilintide endpoints in the verified literature were the 68-week phase 3 reports (PMID 40544433, PMID 40544432). Longer horizons were not covered.
• Non-clinical populations. The published trials enrolled adults with overweight, obesity, or obesity with type 2 diabetes (PMID 34798060, PMID 40544432). Findings do not automatically extend outside those groups.
• Individual-level trajectories. Trial reports describe group-level outcomes at scheduled visits; the phase 2 dose-finding publication was structured around dose comparison rather than individual prediction (PMID 34798060).
• Related but distinct molecules. Work on other amylin receptor agonists, such as the discovery-to-clinical-proof-of-concept report on eloralintide (LY3841136), describes a different compound and cannot be read as cagrilintide data (PMID 41109426).

Reading Timeline Claims Critically

1. Ask which trial a number came from. A figure from the 26-week dose-finding trial (PMID 34798060) is not interchangeable with one from a 68-week phase 3 trial (PMID 40544433).
2. Ask whether cagrilintide was given alone or with semaglutide. The dose-finding trial studied cagrilintide monotherapy (PMID 34798060), whereas the phase 1b, phase 2 diabetes and phase 3 studies examined coadministration (PMID 33894838, PMID 37364590, PMID 40544432).
3. Ask what the comparator was. Placebo-controlled and active-controlled comparisons answer different questions, and the dose-finding trial included both (PMID 34798060).
4. Ask whether a number is pooled. Network meta-analyses blend trials of differing lengths into single estimates (PMID 42419792, PMID 38286487).

Taken together, the published record for cagrilintide spans a phase 1b study of 20 weeks (PMID 33894838), phase 2 work at 26 and 32 weeks (PMID 34798060, PMID 37364590) and phase 3 reporting at 68 weeks (PMID 40544433). Those are the timepoints researchers chose; they are not a schedule for anyone.

References

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial (Lancet, 2021)
• Development of Cagrilintide, a Long-Acting Amylin Analogue (Journal of Medicinal Chemistry, 2021)
• Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (Lancet, 2021)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)
• Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (Lancet, 2023)
• Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (BMJ, 2024)
• Amylin analogs for the treatment of obesity without diabetes: present and future (Expert Review of Clinical Pharmacology, 2024)
• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (New England Journal of Medicine, 2025)
• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2025)
• Weight management treatment in obesity (Medicina Clínica, 2025)
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis (BMJ, 2026)